Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance

The development and approval of ruxolitinib, the first JAK1/2 inhibitor indicated to treat myelofibrosis, has improved patient outcomes, with higher spleen and symptoms responses, improved quality of life, and overall survival. Despite this, several unmet needs remain, including the absence of resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Breccia, Massimo, Palandri, Francesca, Guglielmelli, Paola, Palumbo, Giuseppe Alberto, Malato, Alessandra, Mendicino, Francesco, Ricco, Alessandra, Sant’Antonio, Emanuela, Tiribelli, Mario, Iurlo, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325304/
https://www.ncbi.nlm.nih.gov/pubmed/35877255
http://dx.doi.org/10.3390/curroncol29070395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325304/
https://www.ncbi.nlm.nih.gov/pubmed/35877255
http://dx.doi.org/10.3390/curroncol29070395

Ejemplares similares